It’s hard, but one can be too skeptical about a new technology. If any of the three companies pursuing RNAi for AMD shows substantial success in the clinic, I expect the hackneyed comparisons to antisense and ribozyme technology to immediately cease.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”